News

At ASCRS in Boston, Paul Harasymowycz, MD shared a decade's worth of data on MIGS procedures for primary open-angle glaucoma

Adam Muzychuk, MD, BSc, FRCSC, discusses his ASCRS 2024 presentation on toric lens use for patients with low astigmatism

Greg Kunst, CEO of Aurion Biotech, discusses AURN001, a novel cell therapy targeting corneal endothelial disease

At ASCRS2024, George O. Waring IV, MD, FACS, provides an overview of his presentation highlighting outcomes for LASIK performed using an updated laser ablation algorithm

Investigators presented research on the pre-treatment outcomes during the 2024 ASCRS meeting

Filomena Ribeiro, MD, PhD, FEBO, discusses her presentation on neuroadaptation following the ASCRS Refractive Day

Sean Hanlon, CEO of CoFi, details the patient and provider benefits of recent CareCredit integration

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Lourens van Zyl wanted to set himself apart in a highly competitive surrounding and saw a potential for practice building by offering solutions for presbyopia in patients without cataract. Within a few years this group became a significant segment of his practice in total share. ZEISS PRESBYOND was the game changer for a business success story.

Three IOLs are evaluated in a randomised study

Multimodal imaging and a systemic work-up failed to identify any underlying disorder for the hemorrhages

The UK's Royal National Institute of Blind People is the global distributor of the headset and ARxVision is partnering with the National Federation of the Blind and Vision Australia to expand global accessibility

The glaucoma specialist talks about navigating the world of research, and the realities of motherhood, as a clinician

Investigators analysed the incidence and mortality rates from conjunctival melanoma cases over a 32-year period

An AI-supported telemedicine effort from Siloam Vision and Orbis International

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

The opportunities and challenges presented by CRISPR manipulation

The European Commission is expected to make a decision about the application before the end of June

Laser blended vision is a proven modality for presbyopia treatment, but its principles can be reproduced with EDOF IOLs

AT ELANA 841P from ZEISS is a fully preloaded lens built with leading technologies when it comes to optical performance, biomaterial properties, and IOL design. In this Case of the Month, Dr Luis Fernandez-Vega Cueto-Felgueroso explains why these features motivated him to trial the ZEISS AT ELANA 841P. He also shares his encouraging early outcomes using the AT ELANA 841P that have motivated him to expand its use.

Proteins common to Alzheimer disease play a significant role in glaucoma

Quantitative and qualitative improvement in IOL design

Researchers investigated patients' ability to drive and work following eye injury

A case study emphasises the shifting paradigm in clinical best practices

Good news for patients: use of anti-complement therapies have caused the growth rate of GA lesions to decrease

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology